Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Neoadjuvant Docetaxel/estramustine Prior To Radical Prostatectomy Or External Beam Radiotherapy In High Risk Localized Prostate Cancer: A Phase II Trial.

W. Kim, Y. Whang, R. Pruthi, M. Baggstrom, W. K. Rathmell, J. Rosenman, E. Wallen, L. Goyal, G. Grigson, C. Watkins, P. Godley
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND Patients with locally advanced or organ confined, high risk, prostate cancer are at significant risk of having disease recurrence despite definitive local therapy. We evaluated the 2-year progression-free survival of subjects treated with chemotherapy administered prior to definitive therapy with surgery or radiation. PATIENTS AND METHODS Patients (n = 24) with locally advanced and high risk localized prostate cancer were treated with neoadjuvant docetaxel 36 mg/m2 i.v. weekly for 3 weeks and estramustine 140 mg orally 3 times daily for 3 consecutive days every 28 days prior to definitive treatment with prostatectomy or radiation. RESULTS All evaluable patients, except 1, completed the proposed cycles of neoadjuvant chemotherapy with minimal dose reductions or delays. Of the 22 evaluable patients, 12 underwent radical prostatectomy and 10 underwent external beam radiation therapy. Twenty-one of 22 patients achieved a prostate-specific antigen (PSA) reduction > 25%. There were no pathologic complete responses. With a median follow-up of 24 months, the 2-year progression-free survival was 45%. CONCLUSIONS Our findings support the safety, tolerability, and efficacy of neoadjuvant chemotherapy in patients with men with high risk, locally advanced prostate adenocarcinoma, although the relative contributions of androgen deprivation therapy and docetaxel cannot be determined. The effectiveness of neoadjuvant chemotherapy in preventing prostate cancer relapses should be studied in a randomized trial.
This paper references
10.1016/S0140-6736(02)09408-4
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M. Bolla (2002)
10.1158/1078-0432.CCR-05-0299
Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer
P. Febbo (2005)
10.1016/S1278-3218(98)80023-1
[Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin].
B. Chauvet (1998)
10.1002/cncr.22897
Neoadjuvant docetaxel treatment for locally advanced prostate cancer
C. Magi-Galluzzi (2007)
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
J. Kirkpatrick (1998)
10.1016/J.UROLOGY.2004.01.040
Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
R. Dreicer (2004)
10.1016/S0090-4295(02)01570-4
Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience.
A. Hurtado-coll (2002)
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.
N. Craft (1999)
10.3322/CA.2007.0010
Cancer Statistics, 2008
A. Jemal (2008)
10.1001/JAMA.292.7.821
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
A. D'Amico (2004)
10.1200/JCO.2000.18.5.1050
Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results.
C. Pettaway (2000)
10.1016/S0090-4295(96)00167-7
Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
P. Kupelian (1996)
10.1097/00042307-199905000-00028
Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results
N. Oakley (1999)
10.1056/NEJMOA040720
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
I. Tannock (2004)
10.1016/S0090-4295(00)00914-6
Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
P. Clark (2001)
10.1056/NEJMOA041318
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
D. Petrylak (2004)
10.1016/S0094-0143(05)70386-4
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
C. Pound (1997)
10.1111/j.1464-410X.2007.06760.x
Long‐term follow‐up of a neoadjuvant chemohormonal taxane‐based phase II trial before radical prostatectomy in patients with non‐metastatic high‐risk prostate cancer
T. Prayer-Galetti (2007)
10.1016/S0022-5347(05)65393-1
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
M. Soloway (2002)
10.1016/S0090-4295(02)02519-0
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
M. Hussain (2003)
10.1016/J.UROLONC.2005.11.034
Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.
M. Garzotto (2006)
10.1016/S1078-1439(03)00159-5
Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413
J. Smith (2003)
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
F. Labrie (1993)
10.1016/j.juro.2008.04.012
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
K. Chi (2008)
10.1016/S0022-5347(01)65645-3
Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.
S. Goldenberg (1996)
10.1097/01.JU.0000108122.36893.5A
Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study.
B. Konety (2004)
10.1016/S0360-3016(96)00590-1
Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
P. Kupelian (1997)
10.1046/j.1464-410X.2002.02982.x
Three‐month neoadjuvant hormonal therapy before radical prostatectomy: a 7‐year follow‐up of a randomized controlled trial
G. Aus (2002)
10.1159/000020366
4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate Cancer
C. Schulman (2000)



This paper is referenced by
10.1097/MOU.0b013e328361d467
Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer
T. Dorff (2013)
10.1016/j.clon.2013.04.002
The future of systemic therapies for localised prostate cancer.
B. J. Eigl (2013)
10.1016/J.JURO.2013.02.585
1001 PREOPERATIVE PREDICTIVE FACTORS AND FURTHER RISK STRATIFICATION OF BIOCHEMICAL RECURRENCE IN CLINICALLY LOCALIZED HIGH RISK PROSTATE CANCER
Riu Hamada (2013)
10.1186/1756-8722-7-20
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
M. Thalgott (2014)
10.1016/j.purol.2014.02.005
[Neoadjuvant before surgery treatments: state of the art in prostate cancer].
V. Richard (2014)
10.4103/aja.aja_40_17
Role of chemotherapy in prostate cancer
Rita Nader (2018)
10.1177/2051415816685211
The role of chemotherapy and new targeted agents in the management of primary prostate cancer
S. Kumar (2016)
10.1016/j.eururo.2012.02.031
High-risk prostate cancer: from definition to contemporary management.
P. Bastian (2012)
10.1007/s10147-015-0923-3
Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer
Riu Hamada (2015)
10.1007/s11934-017-0703-x
Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary
Justin T. Matulay (2017)
Chemotherapy in the Treatment of Prostate Cancer — The Past, the Present, and the Future
S. Sundararajan (2014)
10.1016/J.PUROL.2014.02.005
Traitements néoadjuvants préopératoires : mise au point dans le cancer de la prostate
V. Richard (2014)
10.1155/2013/386809
Neoadjuvant Chemotherapy prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer: A Systematic Review
S. Sfoungaristos (2013)
10.1038/nrurol.2014.100
The status of surgery in the management of high-risk prostate cancer
C. Bach (2014)
10.1111/j.1464-410X.2010.09425.x
Neoadjuvant systemic therapy for urological malignancies
G. Sonpavde (2010)
10.1038/pcan.2016.40
The very-high-risk prostate cancer: a contemporary update
R. Mano (2016)
10.1517/14656566.2010.529900
Triptorelin embonate: a 6-month formulation for prostate cancer
P. Whelan (2010)
10.1517/14656566.2012.690398
A systematic review of the role of adjuvant and neoadjuvant pharmacotherapy in patients undergoing radical prostatectomy
S. Sfoungaristos (2012)
10.7282/T34J0GZ6
A cost-effectiveness framework to evaluate a predictive companion diagnostics of selecting men with high risk localized prostate cancer for neoadjuvant or adjuvant chemotherapy in the u.s.
J. He (2015)
Semantic Scholar Logo Some data provided by SemanticScholar